BCR-ABL p210-b3a2 breakpoint-derived pentapeptide vaccine

{
  "id": "MLC-T-ONC-011925",
  "term": "BCR-ABL p210-b3a2 breakpoint-derived pentapeptide vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A multipeptide vaccine consisting of five peptides derived from the bcr-abl p210-b3a2 breakpoint fusion protein with potential antineoplastic activity. Vaccination with bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl p210-b3a2 breakpoint fusion protein. In chronic myelogenous leukemia (CML), fusion genes typically result from the fusion of either bcr exon b2 or exon b3 to abl exon a2, resulting in either a b3a2 or a b2a2 gene fusion product.",
  "synonyms": [
    "p210-B3A2-derived peptide vaccine",
    "CMLVAX100",
    "p210-B3A2 derived peptide vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/bcr-abl-p210-b3a2-breakpoint-derived-pentapeptide-vaccine/"
}